BioPharmX Corporation (NYSE:BPMX) stock is currently pricing at roughly $0.83. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 1 analysts covering the company at $3.00. That suggests shares of the stock may have another 72 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $3.00, which would imply another -161 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 3 “Buy” ratings in place. At the same time, 0 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 0 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.

Analysts at Maxim Group took a look at BPMX shares in a research note released on Apr 15, 2016, and issued a Buy rating to this company. H.C. Wainwright analysts provided their own take on company recently as well. In a research note published on Apr 07, 2016,the house assigned a Buy rating to this stock. According to a piece that hit the wires on Sep 04, 2015, researchers at Sterne Agee CRT reconsidered their prior rating on the stock, and upped it from Perform to Buy.

BioPharmX Corporation (BPMX) Cap Table Analysis

Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 18.52 percent of the stock.

If we take a more granular look, Mr. Kade Thompson is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 7,000,000 shares, representing a total current market value of roughly $5810000. James R. Pekarsky is another major player among company insiders, currently holding 2,500,000 shares as of 3.69%, carrying a current market value of $2075000. Ms. Anja Krammer is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 2,500,000 shares, valued at around $2075000 as of recent close.

We noted a few insider transactions for the stock recently as well.

In a transaction on 2016-11-28, the company’s Director Morlock Stephen Purchased 428,571 company shares for 150000. That means, once accounting for this transaction, the Director is left with a stake of 795,027 shares, carrying a current total market value of $659872. In addition, by means of a transaction dated 2016-08-15, 10% Owner FRANKLIN RESOURCES INC purchased 484,615 shares worth $315000. After that transaction, this investor is left with a total holding of 5,124,615 shares, representing a total investment value of $4253430.45. We also noted a 2016-03-29 transaction in which BPMX 10% Owner FRANKLIN RESOURCES INC purchased 540,000 shares at a stock price of $1.2, carrying a total value of $648000, after which, this insider’s investment stands at 4,640,000 shares, with an overall financial value of $3851200.

BioPharmX Corporation (NYSE:BPMX) Earnings View 

In the company’s last quarter, BPMX EPS moved to $ from $ compared sequentially with the prior quarter. Revenues for the company came in at $M. This stacks up against $M, on a sequential basis.

How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $ per share on $M in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $-0.08 to $-0.06. On a year-over-year basis, that compares with an EPS comp of $.